EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The tiny giants of regeneration: MSC-derived extracellular vesicles as next-generation therapeutics

Tianhe Zhang, Liang Zhang, Xiaoxue Ma, Wenliang Song

Frontiers in Cell and Developmental Biology · 17.07.2025 · 13

DOI: 10.3389/fcell.2025.1612589 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Cell and Developmental Biology, online erschienen am 17.07.2025. Verfasst von Tianhe Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, China. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 140 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) are revolutionizing the field of regenerative medicine, becoming the core carriers of next-generation acellular therapeutic strategies. In contrast to traditional mesenchymal stem cell therapy, these nanoscale “regenerative tiny giants” offer significant advantages, including low immunogenicity, efficient biological barrier penetration, and stable storage. As natural bioactive molecular carriers, MSC-EVs precisely regulate the inflammatory response, angiogenesis, and tissue repair processes in target tissues by delivering functional RNA, proteins, and other signaling elements. They have demonstrated multidimensional therapeutic potential in diseases such as bone and joint regeneration, nerve function reconstruction, myocardial repair, and skin wound healing. Worldwide, 64 registered clinical trials have preliminarily validated the safety and applicability of MSC-EVs across various diseases. Notably, they have shown significant progress in treating severe coronavirus disease 2019 (COVID-19), ischemic stroke, and complex wound healing. However, the lack of standardization in production processes, insufficient targeting for in vivo delivery, and the scarcity of long-term biodistribution data remain core bottlenecks limiting the clinical translation of MSC-EVs. Future interdisciplinary technologies, including 3-dimensional (3D) dynamic culture, genetic engineering, and intelligent slow-release systems, are expected to facilitate the transition of MSC-EVs from the lab to large-scale applications. This shift may transform “injectable regenerative factors” into “programmable nanomedicines”, offering new solutions for precision medicine.

Schlagwörter

Stichwörter der Autor:innen

animalsbioengineeringclinical trialexosomesextracellular vesicleshumansmesenchymal stem cellstherapy

Autor:innen und Institutionen

  • Department of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, China.
  • Department of Neonatology, The Frist Hospital of China Medical University, Shenyang, China.
  • Department of Pediatrics, The Frist Hospital of China Medical University, Shenyang, China.

Zitieren

APA

Zhang, T., Zhang, L., Ma, X., & Song, W. (2025). The tiny giants of regeneration: MSC-derived extracellular vesicles as next-generation therapeutics. Frontiers in Cell and Developmental Biology, 13. https://doi.org/10.3389/fcell.2025.1612589

Vancouver

Zhang T, Zhang L, Ma X, Song W. The tiny giants of regeneration: MSC-derived extracellular vesicles as next-generation therapeutics. Frontiers in Cell and Developmental Biology. 2025;13. doi:10.3389/fcell.2025.1612589

BibTeX
@article{Zhang2025,
  author = {Zhang, Tianhe and Zhang, Liang and Ma, Xiaoxue and Song, Wenliang},
  title = {The tiny giants of regeneration: MSC-derived extracellular vesicles as next-generation therapeutics},
  journal = {Frontiers in Cell and Developmental Biology},
  year = {2025},
  volume = {13},
  doi = {10.3389/fcell.2025.1612589}
}
Kostenlos starten →